Methotrimeprazine Side Effects
Applies to methotrimeprazine: intramuscular solution.
General
The most commonly reported side effects included dry mouth, somnolence, hypotension, and convulsions.[Ref]
Cardiovascular
Common (1% to 10%): Heat stroke, hypotension, QT prolongation
Uncommon (0.1% to 1%): Tachycardia, venous thromboembolism/fatal venous thromboembolism
Rare (0.01% to 0.1%): Cardiac arrest, cardiac rhythm disturbances, ventricular arrhythmias, ventricular fibrillation, ventricular tachycardia
Frequency not reported: Atrial arrhythmias, atrioventricular (AV) block, cardiac arrhythmias, deep vein thrombosis, ECG changes, orthostatic hypotension, postural hypotension, ST depression, sudden cardiac death, Torsade de pointes, T-wave changes, U-wave changes[Ref]
Heat stroke occurred in hot and humid conditions.
Hypotension occurred with use, especially in older patients.
Orthostatic hypotension occurred with high initial oral doses or with initial parenteral doses.
Patients who develop Torsade de pointes should discontinue treatment and should be given therapy to correct imbalances (e.g., acid base disturbances, electrolyte imbalances, hypoxia).[Ref]
Nervous system
Drowsiness, sedation, and/or somnolence usually occurred early in treatment, but gradually disappeared after the first few weeks and/or with a dose adjustment.
Extrapyramidal syndrome includes akathisia, akinesia with/without hypertonia (partially relieved by antiparkinsonian agents), hyperkinetic-hypertonic movements, and/or motor excitation. Extrapyramidal effects typically occurred after prolonged, high-dose treatment; the effect was treated with reductions in dose or with the addition of an antiparkinsonian agent.
Oculogyric crises, spasmodic torticollis, and trismus occurred with early dyskinesia.
Parkinsonism was prolonged with higher doses.
Tardive dyskinesia occurred with prolonged use, may recur if the neuroleptic is discontinued, and may resolve upon rechallenge or with an increase in dose. Antiparkinsonian agents may cause symptom exacerbation.[Ref]
Common (1% to 10%): Drowsiness, sedation, somnolence
Uncommon (0.1% to 1%): Convulsions, parkinsonism
Rare (0.01% to 0.1%): Extrapyramidal effects
Frequency not reported: Akathisia, akinesia with/without hypertonia, anticholinergic syndrome, early dyskinesia, epileptic seizures, hyperkinetic-hypertonic movements, motor excitation, neuroleptic malignant syndrome, oculogyric crises, spasmodic torticollis, tardive dyskinesia, trismus[Ref]
Gastrointestinal
Common (1% to 10%): Dry mouth
Uncommon (0.1% to 1%): Constipation/severe constipation
Very rare (less than 0.01%): Fatal necrotizing enterocolitis/necrotizing enterocolitis
Frequency not reported: Paralytic ileus[Ref]
Severe constipation may occur with treatment, and laxatives may be needed to treat the condition. Patients should report any new or worsening constipation to their healthcare provider.[Ref]
Other
Asthenia usually occurred early in treatment, but gradually disappeared after the first few weeks.[Ref]
Common (1% to 10%): Asthenia
Frequency not reported: Neonatal drug withdrawal syndrome, sudden death/unexplained sudden death, thermoregulation disorders[Ref]
Hematologic
Uncommon (0.1% to 1%): Agranulocytosis, raised erythrocyte sedimentation rate (ESR)
Frequency not reported: Granulocytopenia, leukocytopenia, neutropenia[Ref]
Hypersensitivity
Uncommon (0.1% to 1%): Allergic skin reactions/allergic dermatitis[Ref]
Dermatologic
Uncommon (0.1% to 1%): Photosensitivity/photosensitivity reaction[Ref]
Genitourinary
Uncommon (0.1% to 1%): Urinary retention
Very rare (less than 0.01%): Priapism
Frequency not reported: Amenorrhea, galactorrhea[Ref]
Metabolic
Uncommon (0.1% to 1%): Weight gain
Frequency not reported: Acid base disturbances, diabetic ketoacidosis, electrolyte abnormalities, glucose intolerance/impaired glucose tolerance, hyperglycemia, hyponatremia[Ref]
Weight gain usually occurred in patients receiving prolonged, high-dose treatment.[Ref]
Hepatic
Rare (0.01% to 0.1%): Cholestatic jaundice without liver damage, jaundice
Frequency not reported: Cholestatic liver injury, hepatocellular liver injury, mixed liver injury[Ref]
Psychiatric
Frequency not reported: Anxiety reactions, confusional state, delirium, frigidity, impotence, indifference, mood changes[Ref]
Endocrine
Hyperprolactinemia may result in amenorrhea, frigidity, galactorrhea, gynecomastia, and impotence.[Ref]
Frequency not reported: Gynecomastia, hyperprolactinemia, hypogonadism, syndrome of inappropriate antidiuretic hormone (SIADH) secretion[Ref]
Respiratory
Frequency not reported: Fatal pulmonary embolism/pulmonary embolism, hypoxia[Ref]
Ocular
Frequency not reported: Accommodation disorder, brown deposits in the anterior segment of the eye[Ref]
Brown deposits in the anterior segment of the eye usually do not affect vision, and are caused by accumulation of the drug.[Ref]
Musculoskeletal
Frequency not reported: Decreased bone mineral density[Ref]
Immunologic
Frequency not reported: Positive serology for antinuclear antibodies without clinical lupus erythematosus[Ref]
More about methotrimeprazine
References
1. Cerner Multum, Inc. UK Summary of Product Characteristics.
2. Cerner Multum, Inc. Canadian Product Information. 2015.
3. Product Information. Methoprazine (methotrimeprazine). AA Pharma Inc. 2020.
4. New Zealand Medicines and Medical Devices Safety Authority. MEDSAFE. http://www.medsafe.govt.nz/Profs/Datasheet/DSForm.asp 2020.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.